_3_Kosinski_Pod_Med_2_Infectious_Disease_ABCs_of_MDRO_ESBLs_KPCs_

Overview of Multidrug Resistant Organisms (MDROs)

  • Discussion focuses on gram-negative multidrug resistant organisms (MDROs), specifically ESBLs and KPCs.

  • ESBLs (Extended Spectrum Beta Lactamases) and KPCs (Klebsiella pneumoniae carbapenemases) are similar to MRSA in the gram-positive realm.

  • Understanding gram-negative resistance issues helps in managing culture and sensitivity reports and selecting appropriate empirical antibiotics.

Importance of the Topic

  • Reference to CNS report from Bellevue Hospital that identified Klebsiella pneumonia as a multidrug resistant organism due to resistance patterns.

  • Highlighting the prevalence of MDROs in clinical settings, particularly in patients with diabetic foot infections.

Terms and Definitions

Multidrug Resistant Organisms (MDRO)

  • MDRO: Organisms with decreased susceptibility to multiple antibiotic classes that were previously susceptible.

Extended Spectrum Beta Lactamases (ESBLs)

  • ESBLs: Enzymes produced by certain gram-negative bacteria (e.g., E. coli, Klebsiella) that target extended spectrum cephalosporins (3rd, 4th, and 5th generation).

  • ESBLs hydrolyze beta-lactam antibiotics, rendering them ineffective.

Klebsiella pneumoniae Carbapenemases (KPCs)

  • KPCs: Enzymes that inactivate carbapenems, leading to significant clinical resistance.

  • KPCs can be spread to other gram-negative organisms beyond Klebsiella.

Key Points on Bacterial Resistance Mechanisms

  • There are hundreds of different types of beta-lactamases produced by various organisms, enabling antibiotic resistances.

  • Carbapenems (e.g., imipenem, meropenem, ertapenem) are critical for treating ESBL producers as they are resistant to ESBL activity but can be neutralized by KPCs.

Clinical Significance of ESBLs and KPCs

  • Diagnosis from CNS Reports:

    • Identifying ESBL producers requires checking for resistance to extended spectrum cephalosporins.

    • Analysis of the resistance patterns provides insight into antibiotic selection and potential treatment strategies.

Challenges in Managing Infections

  • Aminoglycosides and Quinolones may have decreased effectiveness against ESBL and KPC producers due to the transfer of resistance genes.

  • Despite availability of carbapenems for treatment, the development of KPCs poses challenges in clinical settings.

Therapeutic Options

Recommended Treatments for ESBL Producers

  • Carbapenems: Preferred choice for severe infections caused by ESBL-producing gram-negative organisms.

Challenges with KPCs

  • KPCs can inactivate carbapenems, making treatment difficult.

  • Potential therapeutic alternatives include tigecycline (broad-spectrum, but concerns about side effects) and colistin (nephrotoxicity and older drug).

  • Ceftaroline: A newer cephalosporin not effective against ESBLs or KPCs.

  • Abobactam: A beta-lactamase inhibitor that, when combined with ceftaroline, offers protection against ESBLs and KPCs.

Historical Context and Evolution of Resistance

  • ESBL production was first recognized in Klebsiella pneumonia in Germany in 1983, and has since spread to other organisms like E. coli.

  • Ongoing issues with emerging drug-resistant strains challenge antibiotic performance, making continuous updates in treatment protocols necessary.

Conclusion

  • Understanding the mechanisms of gram-negative resistance (like ESBL and KPC production) is essential for effective clinical management of infections.

  • Continuous monitoring and adaptation of treatment strategies will be crucial as resistance patterns evolve.